Global Evidence
Global Epidemiology of Pet Obesity
A clinical overview of canine and feline obesity prevalence, life-stage patterns, surveillance gaps, and practice implications.
Use this page as an evidence-informed guide, not a country ranking. Prevalence estimates vary by body condition score system, threshold, sampling frame, assessor type, and record completeness.
Quick Guide
Interpret global prevalence with clinical context.
A compact orientation for using epidemiology data clearly, accurately, and without overstating what the available evidence can support.
Pet obesity is common worldwide, but prevalence estimates are shaped by how and where body condition is measured.
Across available studies, excess body condition is consistently reported as a major clinical burden in dogs and cats. The headline number should always be paired with the study method, population, species, and BCS threshold.
Table of Contents
Page sections
The layout mirrors a guide map: scan the major sections first, then jump directly to the data or clinical interpretation you need.
Evidence overview
Data and methods
Clinical burden
Excess body condition is one of the most common findings in companion animal practice.
The global evidence base is uneven, but the clinical signal is consistent: overweight and obesity are common, often missed, and often under-recorded.
Common across practice-attending populations
Studies across North America, Europe, Australasia, Asia, and Latin America repeatedly show a substantial burden of excess body condition in dogs and cats.
Dogs and cats do not follow the same severity pattern
Canine excess adiposity is more often concentrated in the overweight range. Feline excess adiposity may shift toward obesity with age.
Methodology changes the headline number
BCS scale, threshold, assessor type, sampling frame, and record completeness all influence reported prevalence and limit direct country comparisons.
Regional evidence
Published prevalence data are concentrated in a limited number of regions.
Coverage is strongest in North America, Western Europe, Australia, New Zealand, and parts of East Asia. Underrepresentation should be read as a surveillance gap, not evidence of low risk.
Most developed surveillance base
U.S. data include historical private-practice baselines, repeated APOP clinical surveillance, and large electronic medical record analyses. Canadian and Mexican veterinarian-assessed population data remain limited.
Dense but heterogeneous evidence
Clinician-assessed estimates often report a substantial burden, while record-based figures can be much lower. The gap highlights underdocumentation in routine records.
Canine evidence is stronger than feline evidence
Australia has a large canine prevalence study, while New Zealand includes both EMR-based vaccination data and a regional household feline study with different design constraints.
Clinic-based and geographically restricted
Available studies are concentrated in Japan, China, and South Korea. Continued use of 5-point BCS in some studies limits comparison with 9-point BCS estimates.
Brazil provides the clearest data
Brazilian community-based and clinic-based studies suggest meaningful prevalence, while comparable veterinarian-assessed prevalence data are sparse across much of Latin America.
Africa, the Middle East, and South Asia need surveillance
Published veterinarian-assessed BCS prevalence data are limited or absent across many countries, creating a need for standardized international surveillance.
Selected estimates
Representative findings should be interpreted with their study design.
These examples are a clinical orientation, not a ranked country comparison. Direct comparison is limited by differences in BCS scale, threshold, sampling, and year of collection.
| Region | Dogs | Cats | Method |
|---|---|---|---|
| United States | 59% | 61% | Clinic · 9-pt BCS, ≥6/9 |
| Australia | 41% | — | Clinic · 9-pt BCS |
| Japan | 54.9% | 56% | Clinic · 5-pt BCS |
| New Zealand | 28.4% | 24.5% | EMR · vaccination visits |
| Brazil | 40.5% | 28.7% | Community-based |
Life-stage trajectory
Obesity risk begins early and often peaks in mature animals.
Large-scale U.S. primary-care data show that excess body condition rises sharply from growth through adulthood. Cats reach a substantial adult burden earlier, while dogs continue accumulating burden into maturity.
Dogs: combined overweight and obesity
Life-stage-specific data should not be interpreted as a single pooled U.S. prevalence estimate.
Cats: combined overweight and obesity
The feline trajectory shifts earlier and includes a higher mature-stage obesity-specific burden.
Recognition gap
Prevalence is often underestimated in records and in owner perception.
The same epidemiology that supports routine screening also supports more deliberate, standardized communication about body condition.
Owner concern misses affected pets
Owner descriptions may not match clinician-assigned BCS, especially when excess adiposity has become normalized or is difficult to see, as in many cats.
Record-based estimates can be minimum estimates
Clinical obesity and overweight may be identified by BCS but not consistently coded or documented in routine medical records.
Do not rely on owner concern as the trigger in cats.
Routine clinician-led BCS is essential in both species, but feline excess body condition may be recognized later, after progression into obesity.
Use in practiceClinical impact
What the epidemiology means for practice.
The practical response is not simply more awareness. It requires consistent assessment, documentation, client communication, and earlier prevention.
Make BCS routine
Body condition scoring should be part of every visit, because owner concern alone will miss a meaningful share of affected pets.
Review evidenceStart during growth and transition points
Growth monitoring, nutrition counseling, and peri-gonadectomy feeding guidance should begin before weight gain becomes established.
View life-stage dataDo not wait for cat owners to raise weight
Feline excess body condition may be recognized later, after it has progressed into the obesity range. Clinician-led assessment is essential.
See recognition gapPrograms and research
Building a stronger global evidence base.
Standardized surveillance can help close regional evidence gaps and improve comparability across countries, practice settings, and species.
Global Pet Obesity Initiative
A veterinary-led program to align definitions, clinical staging, communication, and prevention strategies across companion animal practice.
Learn morePet Obesity Prevalence Survey
A framework for clinician-assigned, per-animal BCS surveillance to strengthen prevalence monitoring and support international comparison.
View survey